Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02230085 · ClinicalTrials.gov registry record

Adherence Risk Indicator Validation Study

A clinical trial, sponsored by Fisher and Paykel Healthcare.

Completed
Registry status
110
Enrollment target

NCT02230085 is a clinical trial that has completed, run by Fisher and Paykel Healthcare. The registered enrollment target is 110 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02230085 has completed, sponsored by Fisher and Paykel Healthcare.

COMPLETED
Registry status
110 participants
Enrollment target

Study Summary

While continuous positive airway pressure (CPAP) is the gold standard treatment of obstructive sleep apnea (OSA), this therapy is often discontinued or not used optimally. The adherence risk indicator (ARI) is a statistical model based on answers from a questionnaire. The data collected from this trail allows for closer monitoring of at-risk patients. For the study, participants are provided with a questionnaire prior to starting CPAP therapy for OSA. Participants will be provided with a GSM (Global System for Mobile communication) modem to allow transmission of their CPAP data. Participants data will be retrieved at 7, 14, 21, 30 and 90 days to test the accuracy of the ARI prediction. At the conclusion of the study the GSM unit is returned, and participants continue with CPAP therapy as instructed by their healthcare provider.

Interventions

  • OTHER Administration of the questionnaire and monitoring of CPAP adherence

Trial Details

FieldValue
Enrollment Target 110 participants
Start Date 2014-09
Est. Completion 2015-12

Sponsor

Fisher and Paykel Healthcare

25 total trials

What the Registry Record Tells You About NCT02230085

The ClinicalTrials.gov registry entry for NCT02230085 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fisher and Paykel Healthcare, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Administration of the questionnaire and monitoring of CPAP adherence is the first listed.

NCT02230085 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02230085 about?

NCT02230085 is a clinical study titled "Adherence Risk Indicator Validation Study". While continuous positive airway pressure (CPAP) is the gold standard treatment of obstructive sleep apnea (OSA), this therapy is often discontinued or not used optimally. The adherence risk indicator (ARI) is a statistical model based on answers from a questionnaire. The data collected from this tr...

What is the current status of trial NCT02230085?

This trial is currently completed. The enrollment target is 110 participants. The study started on 2014-09. Estimated completion is 2015-12.

What interventions are being tested in trial NCT02230085?

The interventions under investigation include: Administration of the questionnaire and monitoring of CPAP adherence (OTHER).

Who is sponsoring clinical trial NCT02230085?

This trial is sponsored by Fisher and Paykel Healthcare, which has 25 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.